NuCana (NCNA) Competitors $1.21 0.00 (0.00%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NCNA vs. MRNS, PMCB, AWH, SLGL, WENA, IPA, IMNN, KZIA, CRVO, and KPRXShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Marinus Pharmaceuticals (MRNS), PharmaCyte Biotech (PMCB), Aspira Women's Health (AWH), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), Kazia Therapeutics (KZIA), CervoMed (CRVO), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Marinus Pharmaceuticals PharmaCyte Biotech Aspira Women's Health Sol-Gel Technologies ANEW Medical ImmunoPrecise Antibodies Imunon Kazia Therapeutics CervoMed Kiora Pharmaceuticals NuCana (NASDAQ:NCNA) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment. Does the MarketBeat Community believe in NCNA or MRNS? Marinus Pharmaceuticals received 186 more outperform votes than NuCana when rated by MarketBeat users. However, 67.65% of users gave NuCana an outperform vote while only 67.54% of users gave Marinus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNuCanaOutperform Votes25167.65% Underperform Votes12032.35% Marinus PharmaceuticalsOutperform Votes43767.54% Underperform Votes21032.46% Do analysts rate NCNA or MRNS? NuCana presently has a consensus price target of $25.00, indicating a potential upside of 1,966.12%. Marinus Pharmaceuticals has a consensus price target of $4.79, indicating a potential upside of 1,980.75%. Given Marinus Pharmaceuticals' higher probable upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than NuCana.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Does the media prefer NCNA or MRNS? In the previous week, Marinus Pharmaceuticals had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for Marinus Pharmaceuticals and 0 mentions for NuCana. NuCana's average media sentiment score of 0.00 equaled Marinus Pharmaceuticals'average media sentiment score. Company Overall Sentiment NuCana Neutral Marinus Pharmaceuticals Neutral Do institutionals and insiders believe in NCNA or MRNS? 44.0% of NuCana shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, NCNA or MRNS? NuCana has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Which has preferable earnings and valuation, NCNA or MRNS? NuCana has higher earnings, but lower revenue than Marinus Pharmaceuticals. NuCana is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$34.37M-$10.48-0.12Marinus Pharmaceuticals$30.99M0.41-$141.40M-$2.47-0.09 Is NCNA or MRNS more profitable? NuCana has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. NuCana's return on equity of -314.47% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -314.47% -112.60% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% SummaryMarinus Pharmaceuticals beats NuCana on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.20M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.1210.5990.0517.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.145.094.784.78Net Income-$34.37M$151.83M$120.31M$225.60M7 Day Performance-4.72%-2.14%-1.92%-1.23%1 Month Performance-1.63%-4.56%13.65%0.46%1 Year Performance-81.02%8.87%28.34%15.24% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana2.587 of 5 stars$1.21flat$25.00+1,966.1%-83.8%$3.20MN/A-0.1230Gap UpMRNSMarinus Pharmaceuticals4.3127 of 5 stars$0.23-11.3%$4.79+1,954.0%-97.6%$12.86M$31.47M-0.10110Analyst ForecastNews CoveragePMCBPharmaCyte Biotech0.4225 of 5 stars$1.67-2.9%N/A-24.8%$12.83MN/A2.612Earnings ReportAWHAspira Women's Health1.218 of 5 stars$0.76+1.4%$4.40+478.9%-69.7%$12.67M$9.15M-0.62110Analyst ForecastSLGLSol-Gel Technologies2.4264 of 5 stars$0.45-5.9%$5.00+1,008.2%-66.5%$12.57M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIPAImmunoPrecise Antibodies2.9257 of 5 stars$0.42+4.5%$5.00+1,086.0%-69.5%$12.16M$24.07M-0.5280News CoverageIMNNImunon2.3546 of 5 stars$0.84-1.1%$20.50+2,354.8%+9.2%$12.11M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpKZIAKazia Therapeutics1.7318 of 5 stars$3.58+0.8%$20.00+458.7%-21.6%$11.92M$2.31M0.0012Gap UpCRVOCervoMed2.2198 of 5 stars$1.90flat$42.00+2,110.5%-67.1%$11.72M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeKPRXKiora Pharmaceuticals2.1064 of 5 stars$3.83+15.4%$10.00+161.1%-32.5%$11.49M$16M0.0010Positive NewsGap Up Related Companies and Tools Related Companies Marinus Pharmaceuticals Competitors PharmaCyte Biotech Competitors Aspira Women's Health Competitors Sol-Gel Technologies Competitors ANEW Medical Competitors ImmunoPrecise Antibodies Competitors Imunon Competitors Kazia Therapeutics Competitors CervoMed Competitors Kiora Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NCNA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NCNA Stock Alerts